GlassScriptPhysician profile
Jake William Altier
NPI 1154983096
$2,784.98
in general payments reported to CMS, 2019-2025
24 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2024: $1,107 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.99 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $643.62 | 2023-2025 | Otezla, Tavneos, Otezla |
| Abbvie INC. | $468.52 | 2024-2025 | |
| Janssen Biotech, INC. | $288.65 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $186.55 | 2024-2025 | |
| Ucb, INC. | $144.29 | 2024-2025 | Bimzelx |
| Organon LLC | $119.09 | 2024-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $116.21 | 2024-2025 | |
| Lilly USA, LLC | $98.25 | 2024-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $91.09 | 2024-2025 | Orencia |
| Glaxosmithkline, LLC. | $85.16 | 2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $81.92 | 2024-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $69.50 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $62.42 | 2024 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $62.33 | 2024-2025 | Strensiq |
| Sandoz INC. | $37.72 | 2024-2025 | Hyrimoz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.54 | 2024 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $30.49 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $29.29 | 2025 | |
| Aurinia Pharma U.S., INC. | $28.36 | 2024 | Lupkynis |
| Pfizer INC. | $28.24 | 2024 | |
| Tersera Therapeutics LLC | $25.77 | 2025 | Quzyttir |
| Mallinckrodt Hospital Products INC. | $22.19 | 2025 | Acthar |
| Almatica Pharma LLC | $19.10 | 2024 | Teriparatide |
| Genentech USA, INC. | $14.68 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Altier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.